Synergy analysis for ETO-Cur and TRF combination therapy in colon cancer cells.

NIAID Data Ecosystem2026-03-11 收录

数据链接：

https://figshare.com/articles/dataset/Synergy_analysis_for_ETO-Cur_and_TRF_combination_therapy_in_colon_cancer_cells_/12013773 数据链接链接失效反馈

官方服务：

资源简介：

Synergy analysis for ETO-Cur and TRF combination therapy in colon cancer cells.

创建时间：

2020-03-20

Apatinib remodels the immunosuppressive tumor ecosystem of gastric cancer enhancing anti-PD-1 immunotherapy

免疫治疗机制

癌症联合疗法

Apatinib has been shown to clinically enhance anti-PD-1 immunotherapy for advanced gastric cancer (GC). However, the complexity of GC immunosuppression remains a challenge for precision immunotherapy.

NIAID Data Ecosystem30

Conserved transcriptional connectivity of regulatory T cells in the tumor microenvironment informs novel combination cancer therapy strategies [mouse]. Conserved transcriptional connectivity of regulatory T cells in the tumor microenvironment informs novel combination cancer therapy strategies [mouse]

肿瘤免疫微环境

癌症联合疗法

While regulatory T (Treg) cells are traditionally viewed as professional suppressors of antigen presenting and effector T cells in both autoimmunity and cancer, recent findings of distinct Treg functi

NIAID Data Ecosystem20

Supplemental Table 3 from CRISPR–Drug Combinatorial Screening Identifies Effective Combination Treatments for MTAP-Deleted Cancer

合成致死筛选

癌症联合疗法

Paralog Screens raw data

Figshare2025-09-15 更新20

Combination of a SOS1-KRAS interaction inhibitor with a KRASG12C inhibitor combination can address intrinsic and acquired resistance leading to stronger and more durable response (Quant-Seq).. Combination of a SOS1-KRAS interaction inhibitor with a KRASG12C inhibitor combination can address intrinsic and acquired resistance leading to stronger and more durable response (Quant-Seq).

KRAS突变耐药机制

癌症联合疗法

To investigate the transcriptomic changes associated with KRAS G12C inhibitor Adagrasib resistance and Adagrasib + SOS1 inhibitor (BI-3406) or Adagrasib + EGFR inhibitor (Cetuximab) combination treatm

NIAID Data Ecosystem30

SUMO pulldown, U2OS, proteomics, 4 hour 20 hour 5-Aza-2' deoxycytidine treatment

癌症联合疗法

SUMO化修饰与DNA损伤响应

Combination therapies targeting malignancies aim to increase treatment efficacy and reduce toxicity. Hypomethylating drug 5-Aza-2’-deoxycytidine (5-Aza-2’) enhances transcription of tumor suppressor g

NIAID Data Ecosystem20

Synergy analysis for ETO-Cur and TRF combination therapy in colon cancer cells.

资源简介：

相关数据集